Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Basic): 2010-2025

Historic EPS (Basic) for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $0.43.

  • Catalyst Pharmaceuticals' EPS (Basic) rose 16.22% to $0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.79, marking a year-over-year increase of 43.20%. This contributed to the annual value of $1.38 for FY2024, which is 105.97% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its EPS (Basic) stood at $0.43 for Q3 2025, which was down 0.00% from $0.43 recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' EPS (Basic) peaked at $0.47 during Q1 2025, and registered a low of -$0.29 during Q3 2023.
  • Moreover, its 3-year median value for EPS (Basic) was $0.36 (2023), whereas its average is $0.31.
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 231.82% in 2023, then spiked by 227.59% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EPS (Basic) (Quarterly) stood at $0.09 in 2021, then surged by 166.67% to $0.24 in 2022, then skyrocketed by 37.50% to $0.33 in 2023, then skyrocketed by 39.39% to $0.46 in 2024, then grew by 16.22% to $0.43 in 2025.
  • Its EPS (Basic) was $0.43 in Q3 2025, compared to $0.43 in Q2 2025 and $0.47 in Q1 2025.